12158 related articles for article (PubMed ID: 12487551)
1. CD40 activation as potential tool in malignant neoplasms.
Ottaiano A; Pisano C; De Chiara A; Ascierto PA; Botti G; Barletta E; Apice G; Gridelli C; Iaffaioli VR
Tumori; 2002; 88(5):361-6. PubMed ID: 12487551
[TBL] [Abstract][Full Text] [Related]
2. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
[TBL] [Abstract][Full Text] [Related]
3. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA; Thomas LJ; He LZ; O'Neill T; Widger J; Crocker A; Sundarapandiyan K; Storey JR; Forsberg EM; Weidlick J; Baronas AR; Gergel LE; Boyer JM; Sisson C; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2019 Feb; 68(2):233-245. PubMed ID: 30382327
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders.
Chand Dakal T; Dhabhai B; Agarwal D; Gupta R; Nagda G; Meena AR; Dhakar R; Menon A; Mathur R; Mona ; Yadav V; Sharma A
Immunobiology; 2020 Mar; 225(2):151899. PubMed ID: 31899051
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
Ceglia V; Zurawski S; Montes M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
J Immunol; 2021 Oct; 207(8):2060-2076. PubMed ID: 34551965
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism and function of CD40/CD40L engagement in the immune system.
Elgueta R; Benson MJ; de Vries VC; Wasiuk A; Guo Y; Noelle RJ
Immunol Rev; 2009 May; 229(1):152-72. PubMed ID: 19426221
[TBL] [Abstract][Full Text] [Related]
7. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
8. Limited importance of CD40/CD40L interaction in the B7-dependent generation of anti-MOPC-315 cytotoxic T lymphocyte activity by tumor bearer splenic cells stimulated in vitro in the presence of tumor necrosis factor.
Kalinichenko TV; Mokyr MB
Cancer Immunol Immunother; 1998 Aug; 46(6):293-303. PubMed ID: 9756413
[TBL] [Abstract][Full Text] [Related]
9. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
[TBL] [Abstract][Full Text] [Related]
10. Regulation of CD40L expression on natural killer cells by interleukin-12 and interferon gamma: its role in the elicitation of an effective antitumor immune response.
Jyothi MD; Khar A
Cancer Immunol Immunother; 2000 Dec; 49(10):563-72. PubMed ID: 11129327
[TBL] [Abstract][Full Text] [Related]
11. Murine Fibroblastic Reticular Cells From Lymph Node Interact With CD4+ T Cells Through CD40-CD40L.
Nakayama Y; Brinkman CC; Bromberg JS
Transplantation; 2015 Aug; 99(8):1561-7. PubMed ID: 25856408
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.
Kikuchi T; Moore MA; Crystal RG
Blood; 2000 Jul; 96(1):91-9. PubMed ID: 10891436
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells.
Wykes M; Poudrier J; Lindstedt R; Gray D
Eur J Immunol; 1998 Feb; 28(2):548-59. PubMed ID: 9521065
[TBL] [Abstract][Full Text] [Related]
15. Role for CD40-CD40 ligand interactions in the immune response to solid tumours.
Alexandroff AB; Jackson AM; Paterson T; Haley JL; Ross JA; Longo DL; Murphy WJ; James K; Taub DD
Mol Immunol; 2000 Jun; 37(9):515-26. PubMed ID: 11163401
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD 40 monoclonal antibody.
Geldart T; Illidge T
Leuk Lymphoma; 2005 Aug; 46(8):1105-13. PubMed ID: 16085550
[TBL] [Abstract][Full Text] [Related]
17. Functions of CD40 and Its Ligand, gp39 (CD40L).
Laman JD; Claassen E; Noelle RJ
Crit Rev Immunol; 2017; 37(2-6):371-420. PubMed ID: 29773027
[TBL] [Abstract][Full Text] [Related]
18. Differential CD40/CD40L expression results in counteracting antitumor immune responses.
Murugaiyan G; Agrawal R; Mishra GC; Mitra D; Saha B
J Immunol; 2007 Feb; 178(4):2047-55. PubMed ID: 17277108
[TBL] [Abstract][Full Text] [Related]
19. Immune Check Point CD40-CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells.
Hillebrand RM; Vogt A; Strassburg CP; Gonzalez-Carmona MA; Schmidt-Wolf IGH
Anticancer Res; 2019 Sep; 39(9):4643-4652. PubMed ID: 31519562
[TBL] [Abstract][Full Text] [Related]
20. Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.
Kornbluth RS; Stempniak M; Stone GW
Int Rev Immunol; 2012 Aug; 31(4):279-88. PubMed ID: 22804572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
